Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Tags
- Viking Therapeutics
- orforglipron
- VK2735
- Efruxifermin
- tern-601
- 비만치료제
- GLP-1
- GPCR
- gsbr-1290
- Novo Nordisk
- glp-1 비만
- GLP-1 치료제
- Pegozafermin
- danuglipron
- Mash
- CAR-T in autoimmune
- CAR-T
- il-17 inhibitor
- ct-996
- GLP-1치료제
- Nash
- 노보노디스크
- 바이오스터디
- 제약바이오
- Semaglutide
- 자가면역질환 치료제
- tirzepatide
- VKTX
- lilly
- 경구용 glp-1
Archives
- Today
- Total
목록2024/06/03 (1)
제약바이오 츄롸이츄롸이!~
Structure Therapeutics (NASDAQ: GPCR) - Obesity 임상 2a상 Week 12 결과 발표
https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-its-phase Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its OralGSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (pir.structuretx.com 흠... 생각보다..
개별 스터디
2024. 6. 3. 23:45